TMBR Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 1.61%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Timber Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Timber Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Timber Pharmaceuticals Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 11/29/2023 09:03 AM ET

This chart shows the closing price history over time for TMBR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Timber Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2021John KoconisCEOBuy20,000$0.38$7,600.00View SEC Filing Icon  
11/23/2021Alan MendelsohnInsiderBuy10,000$0.47$4,700.00View SEC Filing Icon  
11/23/2021Edward J. SitarDirectorBuy15,000$0.46$6,900.00View SEC Filing Icon  
9/1/2021Tardimed Sciences LlcMajor ShareholderSell150,500$0.92$138,460.00View SEC Filing Icon  
8/30/2021Tardimed Sciences LlcMajor ShareholderSell100,000$0.93$93,000.004,034,067View SEC Filing Icon  
8/26/2021Tardimed Sciences LlcMajor ShareholderSell100,000$0.92$92,000.004,334,067View SEC Filing Icon  
8/24/2021Tardimed Sciences LlcMajor ShareholderSell100,000$0.93$93,000.004,334,067View SEC Filing Icon  
8/20/2021Tardimed Sciences LlcMajor ShareholderSell50,000$0.91$45,500.004,534,067View SEC Filing Icon  
8/18/2021Tardimed Sciences LlcMajor ShareholderSell75,000$1.00$75,000.004,534,067View SEC Filing Icon  
6/14/2021Tardimed Sciences LlcMajor ShareholderSell146,465$1.27$186,010.554,637,517View SEC Filing Icon  
6/10/2021Tardimed Sciences LlcMajor ShareholderSell185,229$1.26$233,388.545,065,692View SEC Filing Icon  
6/8/2021Tardimed Sciences LlcMajor ShareholderSell305,540$1.29$394,146.605,065,692View SEC Filing Icon  
6/2/2021Tardimed Sciences LlcMajor ShareholderSell66,285$1.27$84,181.95
See Full Table

SEC Filings (Institutional Ownership Changes) for Timber Pharmaceuticals (NYSE:TMBR)

3.62% of Timber Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TMBR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Timber Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2023Tudor Investment Corp Et Al251,037$0.75M0.0%N/A7.319%Search for SEC Filing on Google Icon
8/15/2023Citadel Advisors LLC33,185$81K0.0%-64.9%1.092%Search for SEC Filing on Google Icon
5/16/2023State Street Corp14,442$25K0.0%N/A0.474%Search for SEC Filing on Google Icon
5/12/2023Renaissance Technologies LLC17,700$30K0.0%N/A0.581%Search for SEC Filing on Google Icon
2/13/2023Geode Capital Management LLC19,893$34K0.0%-97.5%0.679%Search for SEC Filing on Google Icon
12/8/2022Bank of New York Mellon Corp291,384$35K0.0%N/A9.945%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.4,124,900$0.50M0.0%+251.7%140.734%Search for SEC Filing on Google Icon
11/15/2022Bank of New York Mellon Corp291,384$35K0.0%N/A9.945%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC871,237$0.34M0.0%+37.7%1.364%Search for SEC Filing on Google Icon
11/17/2021Altium Capital Management LP831,049$0.46M0.1%N/A2.267%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC65,879$80K0.0%N/A0.180%Search for SEC Filing on Google Icon
8/17/2021Price T Rowe Associates Inc. MD69,000$84K0.0%N/A0.188%Search for SEC Filing on Google Icon
8/17/2021Bridgeway Capital Management LLC105,100$0.13M0.0%+108.1%0.287%Search for SEC Filing on Google Icon
8/16/2021State Street Corp108,500$0.13M0.0%N/A0.296%Search for SEC Filing on Google Icon
8/13/2021Renaissance Technologies LLC118,805$0.15M0.0%N/A0.324%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp60,237$73K0.0%N/A0.164%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC163,837$0.20M0.0%+464.4%0.445%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.997,328$1.22M0.0%+1,046.0%2.707%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC25,550$52K0.0%N/A0.069%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC25,550$52K0.0%N/A0.069%Search for SEC Filing on Google Icon
5/18/2021Jane Street Group LLC45,273$92K0.0%N/A0.123%Search for SEC Filing on Google Icon
5/13/2021Bank of New York Mellon Corp24,120$49K0.0%N/A0.066%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC29,029$58K0.0%N/A0.079%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Timber Pharmaceuticals logo
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.
Read More on Timber Pharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: $1.87
Low: $0.34
High: $2.94

52 Week Range

Now: N/A

Volume

26,307 shs

Average Volume

511,937 shs

Market Capitalization

$1.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03